Latest business update on Medigen Biotech Corp.
Medigen’s ongoing business portfolio includes the following:
A .PI-88:
PI-88, a new compound to be used in early stage of liver cancer to prevent recurrence after surgical resection. PI-88 is currently in Phase III clinical trial.
B: OBP-301
OBP-301, a new compound to be used in mid to late stage liver cancer. Co-developed by Medigen and Japan’s Oncolys BioPharma Inc., OBP-301 has obtained the permission from Taiwan’s TFDA and Korea’s MFDA to conduct phase I/II clinical trial in National Taiwan University Medical Hospital and Pusan National University Medical Hospital simultaneously.
C: Preclinical new drug development
1.Monoclonal Antibody (mAb)
The R&D team of Medigen is targeting on therapeutic applications in infectious diseases such as flu virus, RSR, HBV, HCMV and multi-drug resistance S. aureus as well as autoimmune diseases such as RA, IBD, SLE and psoriasis using Human native mAbs.
2. Virus-like particles Vaccine
Medigen has applied for provisional patent to USPTO on technology related to virus-like particles on Aug. 7th, 2014.
D: Molecular Diagnostics
1.Medigen invested USD $3 million through TBG Inc. in January 2014 for the establishment of TBG (Xiamen) Corp. dedicating to the development, manufacture, and marketing of nucleic acid testing kits. The plant located in Haicang Bio Bay, Xiamen is currently under construction.
2.Medigen has signed a two year contract with Hualien Tzu Chi Hospital to provide HLA-typing kits to Buddhist Tzu Chi Stem Cells Center (BTCSCC).
E: Medigen Vaccinology
Medigen Vaccinology Corp. has signed a licensing agreement with NHRI for the development and commercial rights of H5N1, H7N9 and EV71 vaccines. The vaccine plant located in Chupei is currently under construction and expects to complete by 2015.
F: Winston Medical Supply Co.
1.Medigen Biotechnology Corp. acquired 68% equity stake of Winston Medical Supply Co. in January 2014. Winston’s main businesses include ophthalmic products and hormones drugs.
2.Winston’s new manufacturing plant is currently in the reviewing process for PIC/S GMP certification.